Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor

Life Health > Health Insurance > Health Insurance

Bristol-Myers ends work on Hepatitis C drug

X
Your article was successfully shared with the contacts you provided.

On Thursday, Bristol-Myers Squibb said it was halting development of a drug known as BMS-986094 and designed to treat Hepatitis C, after nine patients in a mid-stage clinical trial were hospitalized, one of whom later died from heart failure. Though the connection between the drug trial and heart failure is not yet confirmed, the company issued a statement last night saying development would stop immediately. The turn of events is a huge setback for the company, who paid $2.5 billion in January to acquire Inhibitex, who was developing the drug that became known as BMS-986094. Competing pharmaceuticals companies, including Idenix Pharmaceuticals and Gilead Sciences are also chasing a drug to treat  Hepatitis C, a viral infection that can cause liver scarring and liver cancer.